MECHANISMS OF ACTIVATION OF HEMATOPOIETIC RECOVERY DUE TO FILGASTRIM IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY WITH DOXORUBICIN/DOCETAXEL
Abstract
The effect of recombinant human granulocyte colony-stimulating factor (filgrastim) on hematopoietic recovery was studied. The study included 77 patients with stage III–IV breast cancer who received chemotherapy with oxorubicin/docetaxel. Filgastrim was administered to 30 patients in the intervals between chemotherapy courses. The drug was injected subcutaneously at a dose of 300 mg, twice, on days 8 and 12 days from the last administration of docetaxel. Blood parameters were assessed within 3 cycles of chemotherapy. Filgastrin was shown to stimulate bone marrow granulocytopoiesis depressed by cytostatic drugs. The effect was realized on the level of committed precursors, morphologically differentiated bone marrow and peripheral blood cell elements, being the result of stimulation of the proliferative activity of hematopoietic progenitor cells of granulocytopoiesis under the influence of humoral factors released by cells of the microenvironment, as well as, to a large extent, the acceleration of the maturation of these cells.
About the Authors
Т. Yu. Khrichkova
Research Institute of Pharmacology Regenerative Medicine, Tomsk
Russian Federation
Russian Federation
Khrichkova Tatiana Yurievna, MD, DSc, Senior Researcher, Laboratory of Pathophysiology and Experimental Therapy.
E-mail: tasha93@mail.ru. SPIN-code: 7866-4221.
V. Е. Goldberg
Tomsk Cancer Research Institute
Russian Federation
Russian Federation
Goldberg Viktor Evgenievich, MD, Professor, Head of Chemotherapy Department, Deputy Director for Science and Treatment.
E-mail: goldbergve@mail.ru. SPIN-code: 7587-0560.
N. О. Popova
Tomsk Cancer Research Institute
Russian Federation
Russian Federation
Popova Natalia Olegovna, MD, PhD, Senior Researcher, Chemotherapy Department.
E-mail: popova75tomsk@ mail.ru. SPIN-код: 7672-1029.
Е. I. Simolina
Tomsk Cancer Research Institute
Russian Federation
Russian Federation
Simolina Elena Ivanovna, MD, PhD, Researcher, Chemotherapy Department.
E-mail: simolin12@ sibmail.com. SPIN-код: 9579-0549.
Yu. V. Belevich
Tomsk Cancer Research Institute
Russian Federation
Russian Federation
Belevich Yulia Viktorovna, MD, Junior Researcher, Chemotherapy Department.
E-mail: Belevich- Julia@sibmail.comV. V. Zhdanov
Research Institute of Pharmacology Regenerative Medicine, Tomsk
Russian Federation
Russian Federation
Zhdanov Vadim Vadimovich, MD, Professor, Deputy Director for Science.
E-mail: zvv@pharm.tsu.ru.
L. А. Miroshnichenko
Research Institute of Pharmacology Regenerative Medicine, Tomsk
Russian Federation
Russian Federation
Miroshnichenko Larisa Arkadievna, MD, DSc, Senior Researcher, Laboratory of Pathophysiology and Experimental Therapy.
E-mail: laarmi@yandex.ru. SPIN-code: 3115-3442.
Е. V. Udut
Research Institute of Pharmacology Regenerative Medicine, Tomsk
Russian Federation
Russian Federation
Udut Elena Vladimirovna, MD, DSc, Principal Investigator, Laboratory of Pathophysiology and Experimental Therapy.
E-mail: evu8@mail.ru. SPIN-код: 1713-8040.
Е. V. Simanina
Research Institute of Pharmacology Regenerative Medicine, Tomsk
Russian Federation
Russian Federation
Simanina Elena Vladislavovna, MD, PhD, Senior Researcher, Laboratory of Pathophysiology and Experimental Therapy.
E-mail: Elena_simanina@mail.ru.
References
1. Goldberg Е.D., Dygai А.М., Zhdanov V.V. The role of the hemopoiesis- inducing microenvironment in the mechanisms of the regeneration of hemopoiesis after cytostatic exposure. Tomsk: STT, 1999. 128 p. [in Russain]
2. Dygai A.M., Bekarev A.A., Vereschagin E.I., Zhdanov V.V., Zyuźkov G.N., Udut E.V., Khrichkova T.Yu., Simanina E.V., Stavrova L.A., Miroshnichenko L.A., Chaikovskiy A.V., Madonov P.G., Artamonov A.V. Hemostimulating effects of immobilized hyaluronidase and their mechanisms during cytostatic-induced myelosuppression // Bulletin of Experimental Biology and Medicine. 2010. Vol. 149 (5). P. 528–531. [in Russain]
3. Manzjuk L.V., Аrtamonova Е.V. The Taxotere in breast cancer chemotherapy // Russkij medicinskij zhurnal (Onkologija). 2006. Vol. 14 (24). P. 1753–1757. [in Russain]
4. Miroshnichenko L.A., Zhdanov V.V., Zyuźkov G.N., Simanina E.V., Stavrova L.A., Udut E.V., Khrichkova T.Yu., Minakova M.Yu., Goldberg V.E., Dygai A.M. Mechanisms of hemostimulating effects of granulocytic colony-stimulating factor and pantohematogen in cytostatic myelosuppression // Bulletin of Experimental Biology and Medicine. 2010. Vol. 150 (12). P. 645–649. [in Russain]
5. Anderlini P., Champlin R.E. Biologic and molecular effects of granulocyte colony-stimulating factor in normal individuals: recent findings and current challenges // Blood. 2008. Vol. 111 (4). P. 1767–1772.
6. Barrios L., Poletti O.H. Effects of filgrastim on granulopoietic cells of mice pretreated with methotrexate // Biocell. 2005. Vol. 29 (1). P. 7–14.
7. Dygai A.M., Zhdanov V.V., Miroshnichenko L.A., Zyuz’kov G.N., Udut E.V., Simanina E.V., Stavrova L.A., Khrichkova T.Y., Agafonov V.I. Comparison of specific activity of granulocytopoiesis stimulators after treatment with cytostatics with different mechanisms of action // Bull. Exp. Biol. Med. 2013. Vol. 155 (5). P. 631–635.
8. Herceg D., Vrbanec D. The role of taxanes in breast cancer chemotherapy: what’s new 15 years after? // Lijec. Vjesn. 2009. Vol. 131 (5–6). P. 133–141.
9. Ishikawa T., Shimizu S., Momiyama N. Ichikawa Y, Shimada H. Advanced in breast cancer chemotherapy // Nippon Rinsho. 2006. Vol. 64. P. 529–535.
10. Lyman G.H., Reiner M., Morrow P.K., Crawford J. The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy // Ann. Oncol. 2015. Vol. 26 (7). P. 1452–1458. doi: 10.1093/annonc/mdv174.
11. Nabholtz J.M., Riva A. Taxane/anthracycline combinations: setting a new standard in breast cancer? // Oncologist. 2001. Vol. 6. Suppl. 3. P. 5–12.
12. Pronzato P. New therapeutic options for chemotherapy-resistant metastatic breast cancer: the epothilones // Drugs. 2008. Vol. 68 (2). P. 139–146.
13. Uddin S., Russell P., Farrell M., Davy B., Taylor J., Agrawal S.G. Use of biosimilar filgrastim compared with lenograstim in autologous haematopoietic stem-cell transplant and in sibling allogeneic transplant // Ther. Adv. Hematol. 2015. Vol. 6 (2). P. 53–60. doi: 10.1177/2040620714565962.
Review
For citations:
Khrichkova Т.Yu., Goldberg V.Е., Popova N.О., Simolina Е.I., Belevich Yu.V., Zhdanov V.V., Miroshnichenko L.А., Udut Е.V., Simanina Е.V. MECHANISMS OF ACTIVATION OF HEMATOPOIETIC RECOVERY DUE TO FILGASTRIM IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY WITH DOXORUBICIN/DOCETAXEL. Siberian journal of oncology. 2015;(6):46-51. (In Russ.)
Views:
793
Email this article 
